Northeast Financial Consultants’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-523,756
| Closed | -$491K | – | 322 |
|
|
2020
Q3 | $491K | Hold |
523,756
| – | – | 0.04% | 174 |
|
|
2020
Q2 | $456K | Hold |
523,756
| – | – | 0.04% | 178 |
|
|
2020
Q1 | $434K | Hold |
523,756
| – | – | 0.05% | 172 |
|
|
2019
Q4 | $466K | Sell |
523,756
-170,100
| -25% | -$151K | 0.04% | 189 |
|
|
2019
Q3 | $680K | Buy |
693,856
+142,000
| +26% | +$139K | 0.07% | 159 |
|
|
2019
Q2 | $607K | Buy |
551,856
+142,000
| +35% | +$156K | 0.06% | 168 |
|
|
2019
Q1 | $537K | Buy |
+409,856
| New | +$537K | 0.06% | 173 |
|
|
2014
Q3 | – | Sell |
-156,425
| Closed | -$385K | – | 142 |
|
|
2014
Q2 | $385K | Hold |
156,425
| – | – | 0.22% | 81 |
|
|
2014
Q1 | $415K | Hold |
156,425
| – | – | 0.24% | 78 |
|
|
2013
Q4 | $454K | Buy |
+156,425
| New | +$454K | 0.3% | 62 |
|